Avalo Therapeutics press release ( AVTX ): Q1 GAAP EPS of -$0.98 beats by $0.05 . Cash, cash equivalents and short-term investments were $82.0 million as of March 31, 2026. Net cash used in operating activities was $17.7 million for the three months ended March 31, 2026. Subsequent to March 31, 2026, the Company completed an underwritten public offering of its common stock and pre-funded warrants ...
Avalo Therapeutics press release ( AVTX ): Q1 GAAP EPS of -$0.98 beats by $0.05 . Cash, cash equivalents and short-term investments were $82.0 million as of March 31, 2026. Net cash used in operating activities was $17.7 million for the three months ended March 31, 2026. Subsequent to March 31, 2026, the Company completed an underwritten public offering of its common stock and pre-funded warrants for net proceeds of approximately $405.0 million. Our current cash, cash equivalents, and short-term investments are expected to fund operations into 2029. More on Avalo Therapeutics Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data Avalo Therapeutics prices $375M public offering; shares jump Seeking Alpha’s Quant Rating on Avalo Therapeutics Historical earnings data for Avalo Therapeutics Financial information for Avalo Therapeutics
Gilat Satellite press release ( GILT ): Q1 Non-GAAP EPS of $0.18 beats by $0.14 . Revenue of $110.5M (+20.1% Y/Y) misses by $4.06M . Management’s financial guidance for 2026 is for revenue between $500 to $520 million (vs. consensus of $509.5M), representing a revenue growth rate of approximately 13% at the midpoint. Adjusted EBITDA for 2026 is expected to be between $61 to $66 million, representi...
Gilat Satellite press release ( GILT ): Q1 Non-GAAP EPS of $0.18 beats by $0.14 . Revenue of $110.5M (+20.1% Y/Y) misses by $4.06M . Management’s financial guidance for 2026 is for revenue between $500 to $520 million (vs. consensus of $509.5M), representing a revenue growth rate of approximately 13% at the midpoint. Adjusted EBITDA for 2026 is expected to be between $61 to $66 million, representing a growth rate of approximately 19% at the midpoint. More on Gilat Satellite Gilat Satellite Networks: Better Business, But Less Upside Than Before Gilat Satellite Q1 2026 Earnings Preview Gilat unit secures order worth over $7M for U.S. defense project Seeking Alpha’s Quant Rating on Gilat Satellite Historical earnings data for Gilat Satellite
mohd izzuan SELLAS Life Sciences ( SLS ) added ~16% in extended trading on Wednesday after the cancer drug developer, with its Q1 2026 results, indicated that it will soon conduct the final analysis of a late-stage trial for its lead asset Galinpepimut-S (GPS). The pivotal Phase 3 trial, named REGAL, is designed to evaluate GPS in acute myeloid leukemia, a cancer of the bone marrow and blood. Its ...
mohd izzuan SELLAS Life Sciences ( SLS ) added ~16% in extended trading on Wednesday after the cancer drug developer, with its Q1 2026 results, indicated that it will soon conduct the final analysis of a late-stage trial for its lead asset Galinpepimut-S (GPS). The pivotal Phase 3 trial, named REGAL, is designed to evaluate GPS in acute myeloid leukemia, a cancer of the bone marrow and blood. Its event-driven final analysis is triggered when 80 events are complete. The New York-based biotech said that the company is approaching a major near-term catalyst as the contract research organization responsible for the study has informed it that it has recorded 78 events as of May 11, 2026. Additionally, SLS announced that dosing has begun in a Phase 2 trial designed to test its second most advanced candidate, SLS009, as a first-line option for AML patients who are unlikely to benefit from standard care. As for financials, SELLAS ( SLS ) disclosed approximately $107.1M of cash and cash equivalents as of March 31, indicating a ~49% rise from December 31. “With REGAL approaching its critical readout and SLS009 advancing across clinical and translational fronts, we believe that SELLAS is entering an exciting time with multiple, high-value potential catalysts that could transform the AML treatment landscape.” CEO Angelos Stergiou said. More on SELLAS Life Sciences Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event Sellas Life Sciences: Behind The Big Surge Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst SELLAS Life Sciences GAAP EPS of -$0.05 beats by $0.01 Seeking Alpha’s Quant Rating on SELLAS Life Sciences
Kornit Digital press release ( KRNT ): Q1 Non-GAAP EPS of -$0.01 beats by $0.01 . Revenue of $48.54M (+4.4% Y/Y) beats by $1.87M . AIC revenues increased approximately 103% year over year. ARR at the end of the first quarter was approximately $26.8 million compared with $14.5 million at the end of the prior year period. For the second quarter of 2026, the Company currently expects revenues to be i...
Kornit Digital press release ( KRNT ): Q1 Non-GAAP EPS of -$0.01 beats by $0.01 . Revenue of $48.54M (+4.4% Y/Y) beats by $1.87M . AIC revenues increased approximately 103% year over year. ARR at the end of the first quarter was approximately $26.8 million compared with $14.5 million at the end of the prior year period. For the second quarter of 2026, the Company currently expects revenues to be in the range of $51 million to $55 million vs $50.61M consensus and an adjusted EBITDA margin to be between negative 5% and breakeven. More on Kornit Digital Kornit Digital: Business Model Transition Progressing - Buy Kornit Digital buys PrintFactory to strengthen automation capabilities Seeking Alpha’s Quant Rating on Kornit Digital Historical earnings data for Kornit Digital Financial information for Kornit Digital
cemagraphics Wallbox ( WBX ) and Freenow by Lyft ( LYFT ) have formed a partnership to accelerate taxi electrification across Europe. The partnership combines Wallbox's ( WBX ) charging hardware and fleet management software with the Freenow taxi-first mobility network and driver programs. Under the agreement, Wallbox ( WBX ) will supply public and depot chargers and deploy its smart charging and ...
cemagraphics Wallbox ( WBX ) and Freenow by Lyft ( LYFT ) have formed a partnership to accelerate taxi electrification across Europe. The partnership combines Wallbox's ( WBX ) charging hardware and fleet management software with the Freenow taxi-first mobility network and driver programs. Under the agreement, Wallbox ( WBX ) will supply public and depot chargers and deploy its smart charging and energy-management platform to help taxi operators optimize charging schedules, reduce energy costs, and increase vehicle uptime. Freenow will integrate Wallbox ( WBX ) solutions into its driver support and sustainability initiatives using incentives, local partnerships, and in-app features to steer taxi drivers toward electrified vehicles and accessible charging infrastructure. The program has already launched in Germany, France, the United Kingdom, Ireland, and Spain. Through the partnership, Freenow BEV and PHEV taxi drivers and fleet owners will also be able to access Wallbox ( WBX ) charging solutions tailored to their day-to-day operational needs, whether charging at home or at fleet depots. The offering will include Pulsar Max for individual drivers, as well as Pulsar Pro and eM4 for fleet and shared charging environments. "The shift to electric mobility in the taxi sector will depend on making charging simple, accessible, and suited to the everyday needs of drivers and fleet operators," highlighted Wallbox ( WBX ) Chief Business Officer Ignasi Alastuey. More on Wallbox and Lyft Lyft: Partnership Rides Driving Bookings Growth And Tremendous FCF Wallbox N.V. 2026 Q1 - Results - Earnings Call Presentation Lyft, Inc. (LYFT) Q1 2026 Earnings Call Transcript Lyft emerges as one of the cheapest ride hailing stocks as per SA valuation grades Lyft expects ~20% gross bookings growth and >30% adjusted EBITDA expansion as it closes Gett U.K.
MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates.
MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates.
Tower Semiconductor press release ( TSEM ): Q1 Non-GAAP EPS of $0.57 beats by $0.01 . Revenue of $414M (+15.6% Y/Y) beats by $3.02M . Cash from operating activities, excluding the increase in customer prepayments, was $225 million for the first quarter of 2026 and investments in property and equipment, net, were $156 million. Business Outlook The company guides revenue for the second quarter of 20...
Tower Semiconductor press release ( TSEM ): Q1 Non-GAAP EPS of $0.57 beats by $0.01 . Revenue of $414M (+15.6% Y/Y) beats by $3.02M . Cash from operating activities, excluding the increase in customer prepayments, was $225 million for the first quarter of 2026 and investments in property and equipment, net, were $156 million. Business Outlook The company guides revenue for the second quarter of 2026 to be $455 million vs. consensus of $436.38M , a company record, with an upward or downward range of 5%, reflecting revenue increase of 22% year-over-year and 10% quarter-over-quarter. Company targets sequential quarter-over-quarter revenue and margin growth throughout 2026. More on Tower Semiconductor Tower Semiconductor: Pure-Play Israeli Foundry In A Boom Cycle Tower Semiconductor: Buy The Story, Respect The Risks Tower Semiconductor: The Hidden AI Photonics Winner Tower Semiconductor Q1 2026 Earnings Preview Tower Semiconductor initiated with bullish views at GF Securities